

## **Influence of sex on disease severity in children with COVID-19 and Multisystem Inflammatory Syndrome in Latin America**

Martin Brizuela, MD<sup>1</sup>; Jacopo Lenzi, PhD<sup>2</sup>; Rolando Ulloa-Gutiérrez, MD<sup>3</sup>; Antúnez-Montes Omar Yassef MD<sup>4</sup>; Jorge Alberto Rios Aida MD<sup>5</sup>; Olguita del Aguila, MD<sup>6</sup>; Erick Arteaga-Menchaca MD<sup>7</sup>; Francisco Campos MD<sup>8</sup>; Fadia Uribe MD<sup>8</sup>; Andrea Parra Buitrago, MD<sup>9,10</sup>; Lina Maria Betancur Londoño, MD<sup>9</sup>; Jessica Gómez-Vargas, MD<sup>11</sup>; Adriana Yock-Corrales MD<sup>11</sup>; Danilo Buonsenso MD<sup>12,13,14</sup>

<sup>1</sup> Pediatric Infectious Disease, Hospital isidoro Iriarte, Quilmes, Buenos Aires, Argentina

<sup>2</sup> Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy

<sup>3</sup> Infectious Disease Department. Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera", CCSS, San José, Costa Rica.

<sup>4</sup> Departamento de Docencia e Investigación, Instituto Latinoamericano de Ecografía en Medicina (ILEM), Ciudad de Mexico, Mexico

<sup>5</sup> CLÍNICA JAS MÉDICA, Lima, Perú

<sup>6</sup> Unidad de Infectología Pediátrica del Hospital Nacional Edgardo Rebagliati Martins-Lima-Perú.

<sup>7</sup> Hospital General Regional 200 IMSS, Mexico

<sup>8</sup> Hospital Madre Niño San Bartolome, Lima, Peru

<sup>9</sup> Hospital Pablo Tobon Uribe Medellin, Colombia

<sup>10</sup> Fundacion Neumologica Colombiana, Bogotá, Colombia

<sup>11</sup> Pediatric Emergency Department, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera", CCSS, San José, Costa Rica.

<sup>12</sup> Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy

<sup>13</sup> Dipartimento di Scienze Biotechnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy

<sup>14</sup>Global Health Research Institute, Istituto di Igiene, Università Cattolica del Sacro Cuore, Roma,  
Italia

**Corresponding author:**

Danilo Buonsenso,

Largo A. Gemelli 8, 00168, Roma, Italy.

Email: [danilobuonsenso@gmail.com](mailto:danilobuonsenso@gmail.com)

Tel: 0039 063015 4390

Twitter: @surf4children

## **Summary**

Data from adult studies show that COVID-19 is more severe in men than women. However, no data are available for the pediatric population. For this reason, we performed this study aiming to understand if sex influenced disease severity and outcomes in a large cohort of Latin-American children with COVID-19 and Multisystem Inflammatory Syndrome (MIS-C). We found that a higher percentage of male children developed MIS-C (8.9% vs 5% in females) and died (1.2% and 0.4% in females), although on multivariate adjusted analyses the only statistically significant difference was found in need of hospitalization, with females less frequently admitted compared with boys (25.6% vs 35.4%). This data are preliminary and need further independent studies to better assess the role of sex.

## **Key words**

COVID-19 ; MIS-C ; Sex ; Gender

## INTRODUCTION

More than a year after the description of the first cases of COVID-19 in China, several aspects of this pandemic are still unclear. Among these, there is the different clinical impact of COVID-19 in women and men. Early data from China showed that men were more frequently infected by COVID-19 than women, and men with underlying diseases (diabetes, hypertension and cardiovascular disease) developed severe condition with an increased mortality rate (1). Similar findings were reported from Italy and, subsequently, confirmed almost in all countries.

Several hypothesis have been postulated to support these differences, although definite conclusions have not reached yet. Disparities in sex-specific disease outcomes may be due to sex-specific steroids and activity of X-linked genes which modulate the innate and adaptive immune response to virus infection and influence the immune response (2). The sex-related pre-existing comorbidities, such as hypertension, cardiovascular disease and diabetes, can play a role, since they were associated with severe outcomes and are more frequent in men (3). Also, hormonal and genetic factors can affect ACE2 expression, the receptor of SARS-CoV-2 (4-6), microRNAs expressions and transcription (7), and Vitamin D3 activity (8).

However, if such a differences between sexes is present in the pediatric population has never been analyzed yet. Major pediatric papers mainly focused age as a risk factors of disease severity but, to our knowledge, no sub-analyses assessing sex have been described (9-15). Since sex-hormones or specific habits (alcohol, type-2 diabetes, cardiovascular disease) are less pronounced in the pediatric population, in particular in infants and young children, such an analyses can provide indirect evidence of influence of hormones on COVID-19. Therefore, we performed this study aiming to understand if sex influenced disease severity and outcomes in a large cohort of latin-american children with COVID-19 and Multisystem Inflammatory Syndrome (MIS-C).

## **MATERIALS AND METHODS**

### *Study Design and Participants*

This study is part of an ongoing independent project assessing COVID-19 and MIS-C in Latin American children, already presented elsewhere (12) and with a previous published paper describing an initial group of 409 children with confirmed COVID-19 (14). For the current study, we performed a sub-analysis of a previously used dataset (15) aiming to assess the influence of sex on disease severity. The remaining variables are those previously described and included age, gender, symptoms, imaging, underlying medical conditions, need for hospital and NICU/PICU admission, respiratory and cardiovascular support, other viral co-infections, drugs used to treat COVID-19, development of MIS-C and type of organ involvement, and outcome.

SARS-CoV-2 infection was defined as a positive PCR test on nasopharyngeal swab.

MIS-C was defined according to the CDC criteria: An individual aged <21 years (we only included if younger than 18 years) presenting with i) fever, ii) laboratory evidence of inflammation, and iii) evidence of clinically severe illness requiring hospitalization, with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological); and iiiii) no alternative plausible diagnoses; and iiiiii) positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or exposure to a suspected or confirmed COVID-19 case within the 4 weeks prior to the onset of symptoms.

The study was reviewed and approved by the COVID in South American children—study Group core group and approved by the Ethics Committee of the coordinating center and by each participating center (Mexico: COMINVETICA-30072020-CEI0100120160207; Colombia: PE-CEI-FT-06; Peru: No. 42-IETSI-ESSALUD-2020; Costa Rica: CEC-HNN-243-2020). The study was conducted in accordance with the Declaration of Helsinki and its amendments. No personal or identifiable data were collected during the conduct of this study.

### **Statistical analysis**

Summary statistics were presented as counts and percentages. The association between female sex and COVID-19 clinical outcomes was preliminarily evaluated with crude odds ratios (ORs) and 95% confidence intervals (CIs). Confounding adjustment was performed using a propensity score approach based on inverse-probability weighting. More specifically, we considered the following covariates potentially related with the outcomes and unbalanced across males and females: age, pre-existing medical conditions, immunosuppressants at the time of diagnosis, primary or secondary immunodeficiency, chemotherapy over the last 6 months, pyrexia ( $\geq 38.0/\geq 100.4$  °C/°F), days between symptom onset and diagnosis, administration of systemic corticosteroids, intravenous immunoglobulin therapy, lower respiratory tract infection, and MIS-C diagnosis. Clustered standard errors were used to account for the multicenter design of the study. All data were analyzed using the Stata 15 software (StataCorp. 2017. *Stata Statistical Software: Release 15*. College Station, TX: StataCorp LLC). The significance level was set at 5% and all tests were 2-sided.

## RESULTS

The characteristics of the 990 patients included in the study, overall and by sex, are summarized in Table 1. Among the 484 females, 39 (8.1%) had chest X-ray abnormalities, 124 (25.6%) were admitted to the hospital, 20 (4.1%) were admitted to ICUs, 49 (10.1%) received respiratory support, and 2 (0.4%) died. 24 (5%) were diagnosed with MIS-C. Among 506 males, 53 (10.5%) had chest X-ray abnormalities, 179 (35.4%) were admitted to the hospital, 27 (5.3%) were admitted to ICUs, 69 (13.6%) received respiratory support, and 6 (1.2%) died. 45 (8.9%) were diagnosed with MIS-C. Results of crude and adjusted analysis showing the association between sex and clinical outcomes are shown in Table 2. Following adjustment obtained with a weighting approach based on propensity scores, the only significant outcome was access to the hospital: girls were admitted less frequently than boys (OR = 0.82, P <0.001).

## DISCUSSION

In this study, we aimed to assess the impact of sex on disease severity in a large cohort of Latin American children with COVID-19 and MIS-C. We found that a higher percentage of male children developed MIS-C (8.9% vs 5% in females) and died (1.2% and 0.4% in females), although on multivariate adjusted analyses the only statistically significant difference was found in need of hospitalization, with females less frequently admitted compared with boys (25.6% vs 35.4%). Taken all together, these preliminary data highlight that females can experience a milder disease compared with boys, as suggested in adults. In other reports (6), the females were more affected by hyposmia or anosmia and gustatory dysfunction compared with males; unfortunately, we did not assess these parameters in this study. In our cohort, children had no comorbidities such as hypertension, obesity or type-2 diabetes, therefore these behavioral factors, traditionally more frequent in males, should have not contributed in the described differences. Also, considering that sex hormones may have less impact in children, therefore different microRNAs expressions due to sex-hormones should not be involved as well.

An explanation in of disparity in sex-specific disease outcomes can be found in the activity of X-linked genes, as previously suggested (6), which modulate the innate and adaptive immune response to virus infection and influence the immune response. Also, the male predominance in the COVID-19 pandemic could partially be explained by sex-specific expressions of TMPRSS2 (6).

The activity and expression of the human angiotensin-converting enzyme 2 (ACE2), the functional receptor for the severe acute respiratory syndrome coronavirus (SARS-CoV), can also explain some differences. Age-related differences have been already reported in a review (16). Also, hormonal and genetic factors could lead to ACE2 over-expression in female sex. Gagliardi et al (6) reported that infection with SARS-CoV induces ACE2 down-regulation through binding of the viral Spike protein to ACE2, thus reducing ACE2 expression in the lung and igniting acute respiratory failure (17).

Vitamin D has also received attention in the immune pathogenesis of COVID-19 (17) and Pagano et al hypothesized that the synergy between Vitamin D3 and estrogen could affect the sex differences in the outcome of patients with COVID-19 (18, 19). However, no rigorous data are yet available on this issues and, in our series, Vitamin D levels have not been reported.

Sex may play an important, major role in severity and length of persisting symptoms after the first diagnosis of acute COVID-19. In adults, long covid has been described and it seems more frequent in women (20-21). In children, international experts highlighted the possibility of this disease in childhood as well and recent report seemed to confirm that long covid may affect children as well (22, 23). Considering the autoimmunity has been suggested as a potential pathogenic trigger and the higher frequency of autoimmune disorders in children, the role of sex in long covid, including children, is a priority research topic for the following months.

Our study has limitation to address. First, it was not initially developed to specifically address how sex could influence disease severity, therefore the variables included as well the study power was not tailored to this topic. Also, blood tests, hormones and Vitamin D were not tested and therefore not analyzed. Last, there is no a control group of adult patients from the same area to compare sex differences in different age groups. However, this study is the first one specifically assessing the role of sex in children with COVID-19 and MIS-C.

In conclusion, we found that a slightly more severe course of COVID-19 and MIS-C in boys compared with women in our cohort of Latin American children. This data are preliminary and need further independent studies to better assess the role of sex. In light of the growing evidence of long covid in children, it is important to begin including sex as an important potential variable of severity or symptoms persistence in children with COVID-19.

**Ethic approval:** approved by each institution (codes provided in methods)

**Funding:** no funds received

**Conflicts of interest:** nothing to declare



**Availability of data and material:** available upon request

## References

- 1- Ambrosino I, Barbagelata E, Ortona E, Ruggieri A, Massiah G, Giannico OV, Politi C, Moretti AM. Gender differences in patients with COVID-19: a narrative review. *Monaldi Arch Chest Dis.* 2020 May 25;90(2)
- 2- Ghosh, S. & Klein, R. S. Sex drives dimorphic immune responses to viral infections. *J. Immunol.* 198, 1782–1790 (2017).
- 3- Vardavas, C. I. & Nikitara, K. COVID-19 and smoking: a systematic review of the evidence. *Tob. Induc. Dis.* 18, 20 (2020)
- 4- Bukowska, A. et al. Protective regulation of the ACE2/ACE gene expression by estrogen in human atrial tissue from elderly men. *Exp. Biol. Med. (Maywood)* 242, 1412–1423 (2017).
- 5- Tukiainen, T. et al. Landscape of X chromosome inactivation across human tissues. *Nature* 550, 244–248 (2017).
- 6- Gagliardi MC, Tieri P, Ortona E, Ruggieri A. ACE2 expression and sex disparity in COVID-19. *Cell Death Discov.* 2020 May 26;6:37. doi: 10.1038/s41420-020-0276-1. PMID: 32499922; PMCID: PMC7248455.
- 7- **Pontecorvi G, Bellenghi M, Ortona E, Carè A. microRNAs as new possible actors in gender disparities of Covid-19 pandemic. *Acta Physiol (Oxf).* 2020 Sep;230(1):e13538. doi: 10.1111/apha.13538. Epub 2020 Jul 30. PMID: 32672403; PMCID: PMC7404333.**
- 8- Pagano MT, Peruzzo D, Ruggieri A, Ortona E, Gagliardi MC. Vitamin D and Sex Differences in COVID-19. *Front Endocrinol (Lausanne).* 2020 Sep 30;11:567824. doi: 10.3389/fendo.2020.567824. PMID: 33101200; PMCID: PMC7554594.

- 9- Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis. *JAMA Pediatr.* Sep 2020;doi:10.1001/jamapediatrics.2020.4573
- 10- Götzinger F, Santiago-García B, Noguera-Julián A, Lanaspá M, Lancellata L, Calò Carducci FI, Gabrovská N, Velizarova S, Prunk P, Osterman V, Krivec U, Lo Vecchio A, Shingadia D, Soriano-Arandes A, Melendo S, Lanari M, Pierantoni L, Wagner N, L'Huillier AG, Heininger U, Ritz N, Bandi S, Krajcar N, Roglić S, Santos M, Christiaens C, Creuven M, Buonsenso D, Welch SB, Bogyi M, Brinkmann F, Tebruegge M; ptbnet COVID-19 Study Group. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. *Lancet Child Adolesc Health.* 2020 Sep;4(9):653-661. doi: 10.1016/S2352-4642(20)30177-2. Epub 2020 Jun 25. PMID: 32593339; PMCID: PMC7316447.
- 11- Parri N, Lenge M, Cantoni B, Arrighini A, Romanengo M, Urbino A, Da Dalt L, Verdoni L, Giaccherò R, Lanari M, Musolino AM, Biban P, La Fauci G, Pilotto C, Buonsenso D, Chiossi M, Agostiniani R, Plebani A, Zampogna S, Barbieri MA, De Masi S, Agostoni C, Masi S; CONFIDENCE RESEARCH GROUP. COVID-19 in 17 Italian Pediatric Emergency Departments. *Pediatrics.* 2020 Dec;146(6):e20201235. doi: 10.1542/peds.2020-1235. Epub 2020 Sep 23. PMID: 32968031.
- 12- Parri N, Magistà AM, Marchetti F, Cantoni B, Arrighini A, Romanengo M, Felici E, Urbino A, Da Dalt L, Verdoni L, Armocida B, Covi B, Mariani I, Giaccherò R, Musolino AM, Binotti M, Biban P, Fasoli S, Pilotto C, Nicoloso F, Raggi M, Miorin E, Buonsenso D, Chiossi M, Agostiniani R, Plebani A, Barbieri MA, Lanari M, Arrigo S, Zoia E, Lenge M, Masi S, Barbi E, Lazzerini M; CONFIDENCE and COVID-19 Italian Pediatric Study Networks. Characteristic of COVID-19 infection in pediatric patients: early findings from two Italian Pediatric Research Networks. *Eur J Pediatr.* 2020 Aug;179(8):1315-1323. doi: 10.1007/s00431-020-03683-8

- 13- Antúnez-Montes OY, Escamilla MI, Figueroa-Uribe AF, Arteaga-Menchaca E, Lavariega-Sáráchaga M, Salcedo-Lozada P, Sunohara RA, Melchior P, Del Razo JOF, Tirado-Caballero JC, Tasayco-Muñoz JA, Pinzon-Redondo H, Montes-Fontalvo LV, Ochoa T, Eduardo Campos F, Hernandez R, Limansky L, Del Aguila O, Buonsenso D. COVID-19 in South American Children: A Call For Action. *Pediatr Infect Dis J.* 2020 Oct;39(10):e332-e334. doi: 10.1097/INF.0000000000002851.
- 14- Antúnez-Montes OY, Escamilla MI, Figueroa-Uribe AF, Arteaga-Menchaca E, Lavariega-Saráchaga M, Salcedo-Lozada P, Melchior P, de Oliveira RB, Tirado Caballero JC, Redondo HP, Montes Fontalvo LV, Hernandez R, Chavez C, Campos F, Uribe F, Del Aguila O, Rios Aida JA, Buitrago AP, Betancur Londoño LM, Mendoza Vega LF, Hernández CA, Sali M, Higueta Palacio JE, Gomez-Vargas J, Yock-Corrales A, Buonsenso D. COVID-19 and Multisystem Inflammatory Syndrome in Latin American Children: A Multinational Study. *Pediatr Infect Dis J.* 2020 Oct 12. doi: 10.1097/INF.0000000000002949.
- 15- Adriana Yock-Corrales, Jacopo Lenzi, Rolando Ulloa-Gutiérrez, Jessica Gómez-Vargas, Antúnez-Montes Omar Yassef, Jorge Alberto Rios Aida, Olguita del Aguila, Erick Arteaga-Menchaca, Francisco Campos, Fadia Uribe, Andrea Parra Buitrago, Lina Maria Betancur Londoño, Martin Brizuela, Danilo Buonsenso. Antibiotic prescriptions in children with COVID-19 and Multisystem Inflammatory Syndrome: a multinational experience in 990 cases from Latin America. doi: <https://doi.org/10.1101/2020.12.05.20243568>
- 16- Buonsenso D, Sali M, Pata D, De Rose C, Sanguinetti M, Valentini P, Delogu G. Children and COVID-19: Microbiological and immunological insights. *Pediatr Pulmonol.* 2020 Oct;55(10):2547-2555. doi: 10.1002/ppul.24978. Epub 2020 Jul 30. PMID: 32710652.
- 17- Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System? A Call for Epidemiologic Investigations. *Clin Infect Dis.* 2020 Jul 28;71(15):870-874. doi: 10.1093/cid/ciaa329. PMID: 32215613; PMCID: PMC7184340.
- 18- Turrubiates-Hernández FJ, Sánchez-Zuno GA, González-Estevez G, Hernández-Bello J, Macedo-Ojeda G, Muñoz-Valle JF. Potential immunomodulatory effects of vitamin D in the

- prevention of severe coronavirus disease 2019: An ally for Latin America (Review). *Int J Mol Med*. 2021 Apr;47(4):32. doi: 10.3892/ijmm.2021.4865.
- 19- Pagano MT, Peruzzo D, Ruggieri A, Ortona E, Gagliardi MC. Vitamin D and Sex Differences in COVID-19. *Front Endocrinol (Lausanne)*. 2020 Sep 30;11:567824. doi: 10.3389/fendo.2020.567824.
- 20- Carfi A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. *JAMA*. 2020 Aug 11;324(6):603-605. doi: 10.1001/jama.2020.12603.
- 21- Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Li Y, Xie W, Cui D, Shang L, Fan G, Xu J, Wang G, Wang Y, Zhong J, Wang C, Wang J, Zhang D, Cao B. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet*. 2021 Jan 16;397(10270):220-232. doi: 10.1016/S0140-6736(20)32656-8.
- 22- Munblit D, Buonsenso D, DunnGalvin A, Garralda E, Jones C, Nicholls DE, Swann O, Semple MG, Sigfrid L, Whittaker EA, Warner JO, and the Paediatric Long COVID Working Group. The risk of overlooking children during the COVID-19 pandemic: Paediatric LongCOVID may be a ticking time bomb. *Lancet Child Adolescent Health* 2021; accepted
- 23- Buonsenso D, Munblit D, De Rose C, Sinatti D, Ricchiuto A, Carfi A, Valentini P. Preliminary Evidence on Long COVID in children. *medRxiv* 2021.01.23.21250375; doi: <https://doi.org/10.1101/2021.01.23.21250375>

**Table 1.** Characteristics of the study sample, overall and by sex.

Characteristic	All (n = 990)		Male (n = 506)		Female (n = 484)	
	n	%	n	%	n	%
Age group						
0 y	202	20.4	99	19.6	103	21.3
1–2 y	229	23.1	123	24.3	106	21.9
3–5 y	144	14.5	80	15.8	64	13.2
6–11 y	247	24.9	137	27.1	110	22.7
12–17 y	168	17.0	67	13.2	101	20.9
COVID-19 confirmed by real-time PCR	639	64.5	345	68.2	294	60.7
Positive SARS-CoV-2 IgG	352	35.6	159	31.4	193	39.9
Delay between onset and diagnosis						
0–1 d	437	44.1	234	46.2	203	41.9
2–7 d	460	46.5	236	46.6	224	46.3
>7 d	93	9.4	36	7.1	57	11.8
Likely index case						
Parent	281	28.4	149	29.4	132	27.3
Sibling	14	1.4	6	1.2	8	1.7
Other	120	12.1	63	12.5	57	11.8
Unknown	575	58.1	288	56.9	287	59.3
Medical history						
Known history of BCG vaccine	740	74.7	402	79.4	338	69.8
Pre-existing medical conditions	128	12.9	76	15.0	52	10.7
Immunosuppressants at diagnosis	11	1.1	9	1.8	2	0.4
Primary or secondary immunodeficiency	8	0.8	6	1.2	2	0.4
Chemotherapy over the last 6 months	8	0.8	5	1.0	3	0.6
Symptoms						
Pyrexia ( $\geq 38.0/\geq 100.4$ °C/°F)	677	68.4	364	71.9	313	64.7
Upper respiratory tract infection	466	47.1	243	48.0	223	46.1
Diarrhea and/or vomiting	301	30.4	158	31.2	143	29.5
Lower respiratory tract infection	215	21.7	129	25.5	86	17.8
Headache	104	10.5	52	10.3	52	10.7
Administration of inotropes	29	2.9	19	3.8	10	2.1
Co-infections in respiratory samples(s)	14	1.4	11	2.2	3	0.6
Drugs administration						
Systemic corticosteroids	90	9.1	52	10.3	38	7.9
Intravenous immunoglobulin (IVIG)	60	6.1	39	7.7	21	4.3
Direct acting antiviral drugs	10	1.0	6	1.2	4	0.8
Hydroxychloroquine	9	0.9	5	1.0	4	0.8
MIS-C diagnosis	69	7.0	45	8.9	24	5.0
Country						
Peru	383	38.7	178	35.2	205	42.4
Costa Rica	299	30.2	169	33.4	130	26.9
Argentina	253	25.6	127	25.1	126	26.0
Colombia	43	4.3	25	4.9	18	3.7
Mexico	12	1.2	7	1.4	5	1.0

*Abbreviations:* COVID-19, coronavirus disease 2019; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; IgG, immunoglobulin G; BCG, bacillus Calmette–Guérin; MIS-C, multisystem inflammatory syndrome.

**Table 2.** Crude and adjusted association between female sex and COVID-19 clinical outcomes, expressed as odds ratios (ORs) and 95% confidence intervals (CI).

Outcome	n (%)	Crude analysis			Adjusted analysis*		
		OR	95% CI	P-value	OR	95% CI	P-value
Chest X-ray abnormalities†	92 (9.3)	0.75	0.58–0.96	0.022	1.09	0.86–1.36	0.480
Hospital admission	303 (30.6)	0.63	0.55–0.72	<0.001	0.82	0.78–0.86	<0.001
ICU admission	47 (4.7)	0.76	0.64–0.92	0.004	1.15	0.94–1.40	0.173
Respiratory support‡	118 (11.9)	0.71	0.58–0.88	0.001	1.08	0.87–1.34	0.487
Death	8 (0.8)	0.34	0.07–1.65	0.183	0.43	0.09–2.10	0.297

\*Confounding adjustment obtained with a weighting approach based on propensity scores.

†Pneumonia and/or acute respiratory distress syndrome.

‡Oxygen support, mechanical ventilation and/or continuous positive airway pressure therapy.

Abbreviation: ICU, intensive care unit.